Results of Alphamab's Clinical Trials Support Further Study of Anti-Cancer Drug JSKN003

MT Newswires Live09-16

Alphamab Oncology (HKG:9966) said the results of the two clinical studies of its JSKN003 support further clinical evaluation of the anti-tumor drug, according to a Sunday filing with the Hong Kong Stock Exchange.

The company's phase 1 study of JSKN003 in Australia showed "promising" efficacy in pretreated patients with platinum-resistant ovarian cancer, irrespective of HER2 expression.

Meanwhile, the phase 1 and phase 2 trials in China demonstrated a "promising" objective response rate with high HER2 expressing gastrointestinal tumor.

Shares closed 5% lower during Monday's trading.

Price (HKD): $2.35, Change: $-0.12, Percent Change: -4.86%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2467184488?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-16 18:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2467184488","market":"sh","top_or_hot":-1,"title":"Results of Alphamab's Clinical Trials Support Further Study of Anti-Cancer Drug JSKN003","media":"MT Newswires Live","content":"<html><body><p> Alphamab Oncology (HKG:9966) said the results of the two clinical studies of its JSKN003 support further clinical evaluation of the anti-tumor drug, according to a Sunday filing with the Hong Kong Stock Exchange.</p><p>The company's phase 1 study of JSKN003 in Australia showed \"promising\" efficacy in pretreated patients with platinum-resistant ovarian cancer, irrespective of HER2 expression.</p><p>Meanwhile, the phase 1 and phase 2 trials in China demonstrated a \"promising\" objective response rate with high HER2 expressing gastrointestinal tumor.</p><p>Shares closed 5% lower during Monday's trading.</p><p>Price (HKD): $2.35, Change: $-0.12, Percent Change: -4.86%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Results of Alphamab's Clinical Trials Support Further Study of Anti-Cancer Drug JSKN003</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResults of Alphamab's Clinical Trials Support Further Study of Anti-Cancer Drug JSKN003\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-16 18:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alphamab Oncology (HKG:9966) said the results of the two clinical studies of its JSKN003 support further clinical evaluation of the anti-tumor drug, according to a Sunday filing with the Hong Kong ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4526","symbol_name":"热门中概股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2467184488","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467184488","pubTimestamp":1726481298,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Alphamab Oncology (HKG:9966) said the results of the two clinical studies of its JSKN003 support further clinical evaluation of the anti-tumor drug, according to a Sunday filing with the Hong Kong Sto","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4526":"热门中概股","BK4588":"碎股","HKD":"尚乘数科","BK4585":"ETF&股票定投概念","BK4023":"应用软件","09966":"康宁杰瑞制药-B","BK1574":"生物医药B类股","BK1161":"生物科技"},"translate_title":"康宁杰瑞临床试验结果支持抗癌药JSKN003进一步研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"09966":0.9},"content_text":"Alphamab Oncology (HKG:9966) said the results of the two clinical studies of its JSKN003 support further clinical evaluation of the anti-tumor drug, according to a Sunday filing with the Hong Kong Stock Exchange.The company's phase 1 study of JSKN003 in Australia showed \"promising\" efficacy in pretreated patients with platinum-resistant ovarian cancer, irrespective of HER2 expression.Meanwhile, the phase 1 and phase 2 trials in China demonstrated a \"promising\" objective response rate with high HER2 expressing gastrointestinal tumor.Shares closed 5% lower during Monday's trading.Price (HKD): $2.35, Change: $-0.12, Percent Change: -4.86%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2467184488"}